Soluble urokinase-type plasminogen activator receptor predicts peripheral artery disease severity and outcomes.
atherosclerosis
chronic kidney disease (CKD)
mortality
peripheral artery disease (PAD)
soluble urokinase-type plasminogen activator receptor (suPAR)
Journal
Vascular medicine (London, England)
ISSN: 1477-0377
Titre abrégé: Vasc Med
Pays: England
ID NLM: 9610930
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
pubmed:
16
1
2021
medline:
23
2
2022
entrez:
15
1
2021
Statut:
ppublish
Résumé
Soluble urokinase-type plasminogen activator receptor (suPAR) is associated with chronic kidney disease (CKD) severity and peripheral artery disease (PAD). We hypothesize an association of PAD severity and suPAR in patients without advanced CKD and further risk stratification according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. For study purposes, suPAR was measured in 334 PAD patients (34% women, age 69 (62-78) years, eGFR 68 ± 20 mL/min/1.72 m
Identifiants
pubmed: 33448911
doi: 10.1177/1358863X20982077
pmc: PMC7879231
doi:
Substances chimiques
Biomarkers
0
Receptors, Urokinase Plasminogen Activator
0
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
11-17Références
Nat Med. 2011 Nov 07;17(11):1410-22
pubmed: 22064431
Sci Rep. 2017 Jan 16;7:40627
pubmed: 28091558
Can J Cardiol. 2015 Oct;31(10):1293-302
pubmed: 26118447
Atherosclerosis. 2020 Mar;297:149-156
pubmed: 31948675
Kidney Int Suppl (2011). 2013 Jan;3(1):63-72
pubmed: 25018976
Kidney Int Rep. 2018 May 22;3(5):1100-1109
pubmed: 30197976
Intensive Care Med. 2012 Sep;38(9):1418-28
pubmed: 22706919
PLoS One. 2013 Aug 21;8(8):e71335
pubmed: 23990945
Blood Coagul Fibrinolysis. 2004 Jul;15(5):383-91
pubmed: 15205586
N Engl J Med. 2015 Nov 12;373(20):1916-25
pubmed: 26539835
Atherosclerosis. 2011 May;216(1):237-43
pubmed: 21354571
Int J Cancer. 2017 Jul 1;141(1):191-199
pubmed: 28393357
Atherosclerosis. 2017 Sep;264:108-114
pubmed: 28728756
Med Etika Bioet. 2002 Spring-Summer;9(1-2):12-9
pubmed: 16276663
J Intern Med. 2015 Mar;277(3):362-371
pubmed: 24830873
J Indian Med Assoc. 2009 Jun;107(6):403-5
pubmed: 19886379
Nat Rev Mol Cell Biol. 2002 Dec;3(12):932-43
pubmed: 12461559
J Am Heart Assoc. 2014 Oct 23;3(5):e001118
pubmed: 25341887
Eur J Vasc Endovasc Surg. 2007;33 Suppl 1:S1-75
pubmed: 17140820
Nat Med. 2017 Jan;23(1):100-106
pubmed: 27941791
J Am Soc Nephrol. 2007 Feb;18(2):629-36
pubmed: 17215445
Diabetologia. 2013 Jul;56(7):1542-6
pubmed: 23613086
Scand Cardiovasc J. 2020 Dec;54(6):339-345
pubmed: 32400206
Lancet Diabetes Endocrinol. 2017 Sep;5(9):718-728
pubmed: 28716631
Circulation. 2009 Nov 24;120(21):2053-61
pubmed: 19901192
PLoS One. 2016 Jul 06;11(7):e0158765
pubmed: 27383068
J Am Soc Nephrol. 2009 May;20(5):1069-77
pubmed: 19357254
Nephrol Dial Transplant. 2020 Mar 1;35(3):465-470
pubmed: 30124995
PLoS One. 2015 Sep 18;10(9):e0138718
pubmed: 26380984
Eur Heart J. 2007 Jun;28(12):1462-536
pubmed: 17562668
Kidney Int Rep. 2017 Feb 09;2(3):425-432
pubmed: 29142970
Circ Res. 2015 Apr 24;116(9):1509-26
pubmed: 25908725
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Diabetes Care. 2003 Jan;26 Suppl 1:S5-20
pubmed: 12502614
Ann Rheum Dis. 1999 Aug;58(8):488-92
pubmed: 10419867
Ann Med. 2017 Jun;49(4):291-298
pubmed: 27665938
J Am Heart Assoc. 2018 May 1;7(9):
pubmed: 29716888
PLoS One. 2015 Jul 13;10(7):e0132869
pubmed: 26167688
Ann Intern Med. 2012 Oct 2;157(7):471-81
pubmed: 23027318
Nat Med. 2011 Jul 31;17(8):952-60
pubmed: 21804539